Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Global $41 Bn Respiratory Drugs Market to 2023 - Leading Players are GSK, AstraZeneca and Boehringer Ingelheim

This image opens in the lightbox

News provided by

Research and Markets

12 Oct, 2017, 17:45 GMT

Share this article

Share toX

Share this article

Share toX

DUBLIN, October 12, 2017 /PRNewswire/ --

The "Global Respiratory Drugs Market to 2023 - A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth Drivers" report has been added to Research and Markets' offering.

Global revenue from the respiratory market is forecast to increase from $30.9 billion in 2016 to $41.3 billion in 2023, at a compound annual growth rate of 4.23%.

Recently approved products in COPD include multiple LABA/LAMA fixed-dose combinations, some of which are forecast to generate over $1 billion by 2023, and include GlaxoSmithKline (GSK)'s triple-combination therapy (fluticasone furoate plus umeclidinium bromide plus vilanterol trifenatate).

The approval of novel biologics in the asthma market, including interleukin (IL)-targeting Nucala (mepolizumab), marketed by GSK, is also forecast to have a strong commercial impact on the market. Notable drivers of growth in the cystic fibrosis (CF) market are the recently approved disease-modifying therapies Kalydeco (ivacaftor) and Orkambi (lumacaftor/ivacaftor), both from Vertex.

Respiratory therapy area consists of indications that affect the lungs, bronchi, trachea, larynx, pharynx and nose in different ways, such as the scarring of lung tissue or the excessive production of mucus. Respiratory disease most commonly results in breathing difficulties, which can lead to disruptions in sleep, wheezing, anxiety and stress. In more severe cases shortness of breath (dyspnea) can limit physical activity, affecting both the quality of life and life expectancy of sufferers. The cause of respiratory disorders varies significantly across each indication and includes factors such as environment, occupation, genetic predisposition and aging.

In 2016, GSK was the leading company in terms of revenue generated from respiratory disorder products, accounting for 30.3% of the market, while Vertex had a small market share of 5.3%. However, the emergence of cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapies, which are considered disease-modifying therapies for CF, an indication which has traditionally only had symptomatic treatments, is set to have a substantial clinical and commercial impact. There are only two of these products on the market, Orkambi and Kalydeco, both of which were developed by Vertex.

Key Topics Covered:

1 Table of Contents

2 Introduction
2.1 Therapy Area Introduction
2.2 Symptoms
2.3 Diagnosis
2.3.1 Asthma
2.3.2 Chronic Obstructive Pulmonary Disease
2.3.3 Idiopathic Pulmonary Fibrosis
2.3.4 Cystic Fibrosis
2.4 Etiology and Pathophysiology
2.4.1 Asthma
2.4.2 Chronic Obstructive Pulmonary Disease
2.4.3 Idiopathic Pulmonary Fibrosis
2.4.4 Cystic Fibrosis
2.5 Epidemiology
2.5.1 Asthma
2.5.2 Chronic Obstructive Pulmonary Disease
2.5.3 Idiopathic Pulmonary Fibrosis
2.5.4 Cystic Fibrosis
2.6 Prognosis and Disease Staging
2.6.1 Asthma
2.6.2 Chronic Obstructive Pulmonary Disease
2.6.3 Idiopathic Pulmonary Fibrosis
2.6.4 Cystic Fibrosis
2.7 Treatment
2.7.1 Asthma
2.7.2 Chronic Obstructive Pulmonary Disease
2.7.3 Idiopathic Pulmonary Fibrosis
2.7.4 Cystic Fibrosis

3 Key Marketed Products
3.1 Overview
3.2 Advair - GSK
3.3 Symbicort - AstraZeneca/Astellas
3.4 Spiriva - Boehringer Ingelheim
3.5 Xolair - Roche/Novartis
3.6 Ventolin - GSK
3.7 Pulmicort - Astra Zeneca
3.8 Orkambi - Vertex
3.9 Relvar/Breo Ellipta - GSK
3.10 Singulair - Merck & Co.
3.11 Esbriet - Roche
3.12 Kalydeco - Vertex
3.13 Conclusion

4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.5 Assessment of Key Pipeline Products
4.5.1 Ivacaftor and Tezacaftor - Vertex
4.5.2 (Fluticasone Furoate plus Umeclidinium Bromide plus Vilanterol Trifenatate) - GlaxoSmithKline/Innoviva
4.5.3 Dupixent - Regeneron Pharmaceuticals/Sanofi
4.5.4 Benralizumab - AstraZeneca/Medimmune
4.5.5 Tralokinumab - AstraZeneca
4.5.6 PT010 (Budesonide plus Formoterol Fumarate plus Glycopyrrolate) - AstraZeneca/Pearl Therapeutics
4.5.7 Conclusion
4.6 Conclusion

5 Multi-scenario Market Forecast to 2023
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 G Protein-Coupled Receptors
5.3.2 Immune/Inflammatory Mediators
5.3.3 Transcription Factors
5.3.4 Signal Transduction
5.3.5 CFTR Modulator

6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 GlaxoSmithKline
6.1.2 Vertex
6.1.3 AstraZeneca
6.1.4 Roche
6.1.5 Boehringer Ingelheim
6.1.6 Novartis
6.1.7 Teva
6.1.8 Sumitomo Dainippon
6.1.9 Regeneron
6.1.10 Merck & Co.
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deal by Region, Year and Value
7.1.2 Deals by Stage of Development and Value
7.1.3 Deals by Molecule Type and Molecular Target
7.1.4 Table for Licensing Deals Valued Above $100m
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Stage of Development and Value
7.2.3 Deals by Molecule Type, Mechanism of Action and Value
7.2.4 Table for Co-development Deals Valued Above $100m

8 Appendix
8.1 Bibliography
8.2 All Pipeline Drugs by Phase
8.2.1 Discovery
8.2.2 Preclinical
8.2.3 IND/CTA-Filed/Phase 0
8.2.4 Phase I
8.2.5 Phase II
8.2.6 Phase III
8.2.7 Pre-registration
8.3 Abbreviations
8.4 Methodology

Companies Mentioned

  • Astra Zeneca
  • Astellas
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Merck & Co.
  • Novartis
  • Regeneron
  • Roche
  • Sumitomo Dainippon
  • Teva
  • Vertex

For more information about this report visit https://www.researchandmarkets.com/research/jwb4rr/global

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.